At what enterprise value was PRODIET acquired in 2025?

You can find the full valuation details of PRODIET on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of PRODIET when it was acquired by NUTRISENS?

The exact EV/EBITDA multiple for PRODIET is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was PRODIET acquired by NUTRISENS?

PRODIET was acquired by NUTRISENS in 2025.

What was the revenue of PRODIET at the time of the deal?

The revenue of PRODIET at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the PRODIET acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PRODIET deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.lesechos.fr/pme-regions/auvergne-rhone-alpes/complements-alimentaires-nutrisens-setend-a-linternational-2155307

← DATABASE

Home Database Healthcare & PharmaPRODIET

03/2025

PRODIET acquired by NUTRISENS

BRAZIL Life Sciences / Nutrition & Dietary Supplements REV 25M - 50M EUR

Context

Nutrisens Group has acquired a majority stake in Prodiet Medical Nutrition, a Brazilian leader in clinical nutrition. The founders of Prodiet, Armando Tortelli and Ana Paula Celes, retain a minority stake and will continue to support the company's growth, while Gabriel Tortelli remains as CEO. This acquisition marks a major step in Nutrisens' international expansion strategy, providing a strong platform to address the Latin American market. The deal is expected to generate significant commercial synergies through cross-selling portfolios and optimizing innovation and sourcing capabilities.

PRODIET, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2005, Prodiet Medical Nutrition is a fast-growing specialist in clinical nutrition. The company develops and manufactures a wide range of oral and enteral nutrition products (liquids and powders) for patients with specific needs, such as neurological conditions, post-surgery recovery, and oncology. Prodiet operates two production facilities in Curitiba and employs approximately 200 people. It distributes its products through hospitals, pharmacies, and e-commerce across Brazil and exports to international markets.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
04/2025	INSTITUT MERIEUX / ARCHIMED	CEVA SANTE ANIMALE	FRANCE	Animal Health
04/2025	CINVEN	NUTRISENS	FRANCE	Nutrition & Dietary Supplements
03/2025	SIPAREX	LABORATOIRE POLIDIS	FRANCE	Medical Consumables
03/2025	ZYDUS	AMPLITUDE SURGICAL	FRANCE	Implants & Prosthetics
03/2025	LBO FRANCE	HEMODIA	FRANCE	Medical Devices
02/2025	NOVONESIS	FEED ENZYME ALLIANCE	DENMARK	Animal Health
02/2025	EURAZEO / TURENNE CAPITAL / KURMA PARTNERS	GERMITEC	FRANCE	Medical Devices
01/2025	QUADRIVIO GROUP	MIR - MEDICAL INTERNATIONAL RESEARCH	ITALY	Diagnostic Equipment
12/2024	NEXTSTAGE / IK PARTNERS	EUROBIO SCIENTIFIC	FRANCE	Diagnostic Equipment
12/2024	UI INVESTISSEMENT	DIDACTIC	FRANCE	Medical Consumables

REFERENCES

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PRODIET by NUTRISENS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.